Depends how one looks at it hey?
Cardiocel is proven and will be an earner. Compared to PBT which is $100m more expensive and losing more money than AHZ, PBT has double the cash on hand(ignored as it'll be spent for both), AHZ has revenue of 8m p/a whereas PBT has none, nothing proved or able to sell.
One can say both are overpriced/valued but thats not exactly how the stockmarket works and you would know this meerkat.
Look at XRO for example.
PPL were paying 40 times earnings for NCM a couple of years back.
The upside is present for cardiocel. FDA and IF phase 1 of HSV looks good, the speculation continues.
Whats the speculation for NCM or XRO?
Whats the guarantee for NCM, XRO and PBT.
no need to worry, page-7
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.00 |
Change
-0.150(0.99%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.10 | $14.85 | $133.6K | 8.912K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $14.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 510 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |